Treating Huntingon's chorea can be complicated. Sometimes it’s difficult to follow all of your doctor’s instructions. Use these tips to help ensure you take AUSTEDO as prescribed:
Your prescribed dose for Huntington’s disease chorea may require a combination of tablet strengths
Your doctor may increase your dose of AUSTEDO each week for several weeks to find the dose that is appropriate for you. This process is known as titration. It’s important to follow your doctor’s instructions during this process. While some people may start to experience treatment benefits sooner, it may take up to 12 weeks to reach the full benefits of AUSTEDO.
tablets not actual size
tablets not actual size
Do not chew, crush, or break tablets before swallowing. If you cannot swallow AUSTEDO whole, tell your healthcare provider. You may need a different medicine.
Set a routine
- Create and follow a dosing routine. Remember that AUSTEDO must be taken exactly as prescribed.
- Set an alarm as a treatment reminder.
- Keep your AUSTEDO tablets in the same place so you know where they are.
Record your treatment
- Use the HD Chorea Treatment Tracking Guide to help set and achieve treatment goals, record when you take AUSTEDO, and note any questions you may have for your doctor.
Have a plan
- Before starting AUSTEDO, talk to your doctor about what to do if you miss a dose.
- Add your dosing schedule to your other daily routines so you will be less likely to miss a dose.
- Tell your doctor if you stop taking AUSTEDO for more than 1 week. Do not take another dose until you talk to your doctor.
For additional information about how to take AUSTEDO, please read the Medication Guide.
Ask your doctor if you have any questions about taking AUSTEDO.
Switching from tetrabenazine1,2
When switching to AUSTEDO from tetrabenazine, you can start AUSTEDO the day after you stop tetrabenazine. This means you can continue treating your HD chorea without missing a dose.
In a clinical study, 37 people with HD chorea switched overnight from tetrabenazine to AUSTEDO. People in the study received AUSTEDO at approximately half the dose of tetrabenazine.
Models are not
Download the Huntington’s chorea Treatment Tracking Guide to record when AUSTEDO is taken and note any questions for your doctor.Download the guide
You are about to leave this site
You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.
To redeem this offer, you must have a valid prescription for AUSTEDO®. No substitutions permitted. Commercially insured patients with coverage for AUSTEDO® may pay no out-of-pocket costs. Commercially insured patients whose insurer requires a prior authorization for AUSTEDO® may receive a 30 day supply of AUSTEDO® (up to a total of three prescriptions with only one prescription per AUSTEDO® strength or NDC) under the Program while their prior authorization is pending. If the prior authorization is approved by the commercial insurer, then the individual remains eligible for the Program. If the prior authorization is denied by the commercial insurer, then the individual is no longer eligible for this Program and may not receive any additional Program benefits. Maximum annual benefits apply and out-of-pocket expenses may vary. Patient is responsible for costs above maximum benefit amounts. If you have any questions regarding your eligibility or benefits, please call the AUSTEDO® Copay Program at 1-800-887-8100.
You are not eligible for this offer if your prescriptions are paid for in part or full by any state or federally funded programs, including but not limited to Medicare or Medicaid, Medigap, VA, DOD, TRICARE, or by private health benefit programs which reimburse you for the entire cost of your prescription drugs. This offer is not valid for patients who are Medicare eligible and are enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (i.e., patients who are eligible for Medicare Part D but receive a prescription drug benefit through a former employer). You are not eligible for this offer if you are uninsured or a cash-paying patient. This offer is void in California if an AB-rated generic drug is available for the product. By redeeming this offer, you acknowledge that you are an eligible patient and you understand and agree to comply with the terms and if copied, transferred, purchased, altered or traded and where prohibited and restricted by law. conditions of this offer. Void if copied, transferred, purchased, altered or traded and where prohibited and restricted by law. Program managed by PSKW, LLC on behalf of Teva Pharmaceuticals. The parties reserve the right to change or discontinue this offer at any time without notice. This offer is not health insurance.
This offer is restricted to residents of the United States and Puerto Rico and valid only at participating pharmacies. This offer is limited to one per customer and may not be used with any other discount, coupon or offer. Offer expires December 31, 2019.To the Pharmacist:
When you apply this offer, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental program for this prescription.
Pharmacist Instructions: Submit claim to Therapy First Plus. If primary coverage exists, input offer information as secondary coverage and transmit using the COB segment of the NCPDP transaction.
For questions regarding processing, please call the Help Desk 1-800-422-5604 .
AUS-41403 December 2018
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. 2. Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977–982. doi:10.1001/jamaneurol.2017.1352